Related Experiment Video
Updated: Jul 13, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
R Corti1, J C Burnett, J L Rouleau
1CardioVascular Center, Cardiology, University Hospital Zurich, Switzerland. cardiotfl@gmx.ch
Circulation
|October 10, 2001
Summary
Vasopeptidase inhibitors, by blocking both ACE and neutral endopeptidase (NEP), offer a promising new treatment for cardiovascular diseases. This dual inhibition enhances beneficial natriuretic peptides and kinins, reducing blood pressure and improving vascular function.
Area of Science:
- Cardiovascular Physiology
- Pharmacology
Background:
- The cardiovascular system relies on hemodynamic and neurohumoral regulation for homeostasis.
- Dysregulation of neurohumoral systems contributes to cardiovascular diseases like hypertension and heart failure.
- Neutral endopeptidase (NEP) degrades natriuretic peptides, kinins, and adrenomedullin, which are crucial for vascular health.
Purpose of the Study:
- To explore the therapeutic potential of inhibiting neutral endopeptidase (NEP) in cardiovascular disease.
- To evaluate the combined inhibition of ACE and NEP as a novel therapeutic strategy.
Main Methods:
- Investigated the enzymatic activity and substrate specificity of neutral endopeptidase (NEP).
- Examined the effects of NEP inhibition on natriuretic peptides, kinins, and adrenomedullin levels.
- Assessed the impact of combined ACE and NEP inhibition on vasoconstriction, vasodilation, and blood pressure.
Main Results:
- Inhibition of NEP increases levels of natriuretic peptides (ANP, BNP, CNP), bradykinin, and adrenomedullin.
- Combined inhibition of ACE and NEP reduces vasoconstriction and enhances vasodilation.
- This dual inhibition improves sodium/water balance, decreases peripheral vascular resistance, and lowers blood pressure.
Conclusions:
- Combined inhibition of ACE and neutral endopeptidase (NEP) represents a novel therapeutic approach for cardiovascular conditions.
- Vasopeptidase inhibitors show promise in treating hypertension, atherosclerosis, and heart failure by modulating multiple neurohumoral systems.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...